[A trial of the use of a new thrombolytic preparation--recombinant tissue-type plasminogen activator--in myocardial infarct patients].
Search for more effective and safe drugs has recently led to the design of second-generation thrombolytic enzymes one of which is recombinant tissue plasminogen activator. A total of 80 patients including 41 who received tissue plasminogen activator (TPA) (Group 1), 39 on streptokinase (SK) (Group 2) were examined. By the 90th minute of thrombolytic infusion, coronary blood flow was recovered in 27 (66%) patients from Group 1 and 19 (49%) from Group 2 (p = 0.12). A decrease in fibrinogen concentration by less than 1 g/l was seen in 7 (18.4%) patients from Group 1 and in 29 (82.9%) patients from Group 2 (p = 0.00005). The levels of fibrinogen and plasminogen during 36 hours of initiation of thrombolytic infusion were statistically significantly lower in Group 2. The incidence of hemorrhages was the same in the two groups and equal to 26.8 and 28.0% in Groups 1 and 2, respectively. All the patients had no hemorrhages requiring transfusion of blood and its substitutes, as well as no cerebral circulatory disorders in the first week of the disease.
A N
AN
Plotnikov
I I
II
Staroverov
I A
IA
Tagieva
B N
BN
Dorogun
E V
EV
Pomerantsev
A B
AB
Dobrovol'skiĭ
M Ia
MIa
Ruda
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D017023:Coronary Angiography / Q000187:drug effects; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator